[{"data":1,"prerenderedAt":320},["ShallowReactive",2],{"gql:data:KkupeA4Yl0FFIDWkg9wyv0tlQF_agaOBfY7WHBjm8MA":3,"gql:data:P04TTYpz2Xg26ViDSjffhcB_87AQtSlPepebn_FOrG8":87,"gql:data:zx7VWT8T76NYguf9J66C_gR2bf4JQJ-Gsfmk46Ekjf8":200},{"_site":4,"allMenuCtas":33,"allMenuItems":44,"allFooterLinks":71,"allCategories":76},{"globalSeo":5,"favicon":8,"faviconMetaTags":10,"locales":31},{"siteName":6,"titleSuffix":7},"https://cellsighttech.com"," | Realising the hope",{"url":9},"https://www.datocms-assets.com/132841/1717490991-logoshort.svg",[11,19,23,27],{"tag":12,"content":13,"attributes":14},"link",null,{"sizes":15,"type":16,"rel":17,"href":18},"16x16","image/svg","icon","https://www.datocms-assets.com/132841/1717490991-logoshort.svg?auto=format&h=16&w=16",{"tag":12,"content":13,"attributes":20},{"sizes":21,"type":16,"rel":17,"href":22},"32x32","https://www.datocms-assets.com/132841/1717490991-logoshort.svg?auto=format&h=32&w=32",{"tag":12,"content":13,"attributes":24},{"sizes":25,"type":16,"rel":17,"href":26},"96x96","https://www.datocms-assets.com/132841/1717490991-logoshort.svg?auto=format&h=96&w=96",{"tag":12,"content":13,"attributes":28},{"sizes":29,"type":16,"rel":17,"href":30},"192x192","https://www.datocms-assets.com/132841/1717490991-logoshort.svg?auto=format&h=192&w=192",[32],"en",[34,40],{"id":35,"title":36,"reference":13,"externalLink":37,"primary":38,"publishTranslation":39},"7540649","Contact us","",false,true,{"id":41,"title":42,"reference":13,"externalLink":43,"primary":39,"publishTranslation":39},"7540648","Sign up","https://google.com",[45,53,59,65],{"id":46,"children":47,"externalLink":37,"parent":13,"reference":48,"title":52,"description":37,"publishTranslation":39},"7537370",[],{"__typename":49,"_modelApiKey":50,"slug":51},"PageRecord","page","technology","Technology",{"id":54,"children":55,"externalLink":37,"parent":13,"reference":56,"title":58,"description":37,"publishTranslation":39},"7537372",[],{"__typename":49,"_modelApiKey":50,"slug":57},"clinical-trials","Clinical Trials",{"id":60,"children":61,"externalLink":37,"parent":13,"reference":62,"title":64,"description":37,"publishTranslation":39},"ROxnTf15SA-ed2m4fifC-A",[],{"__typename":49,"_modelApiKey":50,"slug":63},"publications","Publications",{"id":66,"children":67,"externalLink":37,"parent":13,"reference":68,"title":70,"description":37,"publishTranslation":39},"7537374",[],{"__typename":49,"_modelApiKey":50,"slug":69},"about","About Us",[72,74],{"externalLink":37,"reference":13,"title":73,"publishTranslation":39},"Terms and conditions",{"externalLink":37,"reference":13,"title":75,"publishTranslation":39},"Privacy",[77,81,84],{"__typename":78,"id":79,"name":80},"CategoryRecord","7538843","Blog",{"__typename":78,"id":82,"name":83},"7538845","Video",{"__typename":78,"id":85,"name":86},"7538844","Webinar",{"page":88},{"_allSlugLocales":89,"_allPublishTranslationLocales":91,"_modelApiKey":50,"id":93,"slug":57,"title":58,"publishTranslation":39,"noIndex":38,"header":94,"main":122,"seo":139,"seoMetadata":13},[90],{"locale":32,"value":57},[92],{"value":39,"locale":32},"ckdleJefRF2Q_zLNGc0Avg",[95],{"__typename":96,"title":97,"backgroundVariant":98,"media":99,"heroPin":113},"SectionHeroRecord","Around the World. \u003Cbr/>\u003Cmark>And Back.\u003C/mark>","World",{"alt":100,"url":101,"width":102,"height":103,"responsiveImage":104},"Map","https://www.datocms-assets.com/132841/1719216267-desktop.png",2880,1920,{"srcSet":105,"webpSrcSet":106,"sizes":107,"src":108,"width":103,"height":109,"aspectRatio":110,"alt":100,"title":100,"bgColor":111,"base64":112},"https://www.datocms-assets.com/132841/1719216267-desktop.png?auto=compress&crop=focalpoint&dpr=0.25&fit=crop&w=1920 480w,https://www.datocms-assets.com/132841/1719216267-desktop.png?auto=compress&crop=focalpoint&dpr=0.5&fit=crop&w=1920 960w,https://www.datocms-assets.com/132841/1719216267-desktop.png?auto=compress&crop=focalpoint&dpr=0.75&fit=crop&w=1920 1440w,https://www.datocms-assets.com/132841/1719216267-desktop.png?auto=compress&crop=focalpoint&fit=crop&w=1920 1920w,https://www.datocms-assets.com/132841/1719216267-desktop.png?auto=compress&crop=focalpoint&dpr=1.5&fit=crop&w=1920 2880w","https://www.datocms-assets.com/132841/1719216267-desktop.png?auto=compress&crop=focalpoint&dpr=0.25&fit=crop&fm=webp&w=1920 480w,https://www.datocms-assets.com/132841/1719216267-desktop.png?auto=compress&crop=focalpoint&dpr=0.5&fit=crop&fm=webp&w=1920 960w,https://www.datocms-assets.com/132841/1719216267-desktop.png?auto=compress&crop=focalpoint&dpr=0.75&fit=crop&fm=webp&w=1920 1440w,https://www.datocms-assets.com/132841/1719216267-desktop.png?auto=compress&crop=focalpoint&fit=crop&fm=webp&w=1920 1920w,https://www.datocms-assets.com/132841/1719216267-desktop.png?auto=compress&crop=focalpoint&dpr=1.5&fit=crop&fm=webp&w=1920 2880w","(max-width: 1920px) 100vw, 1920px","https://www.datocms-assets.com/132841/1719216267-desktop.png?auto=compress&crop=focalpoint&fit=crop&w=1920",1280,1.5,"#fdfefd","data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABgAAAAQAQMAAAA26i3WAAAAA1BMVEXu6ugORrFcAAAAAXRSTlMAQObYZgAAAA9JREFUeNpjYWBgYKEAAwAIwABB6VkCaQAAAABJRU5ErkJggg==",[114,116,118,120],{"pinTitle":115,"pinSubTitle":37,"colorVariation":38},"Sixteen clinical protocols",{"pinTitle":117,"pinSubTitle":37,"colorVariation":38},"Fourteen clinical production sites",{"pinTitle":119,"pinSubTitle":37,"colorVariation":38},"A single synthesis run caters to multiple patients",{"pinTitle":121,"pinSubTitle":37,"colorVariation":38},"Doses can be shipped to imaging facilities 4 hrs away from production sites",[123,128,133],{"__typename":124,"id":125,"outerColor":13,"innerColor":126,"pullUp":39},"SectionRowRecord","NUCqgdqSSmeMrudZTzU2rw",{"hex":127},"#FFFFFF",{"__typename":129,"id":130,"topTitle":131,"title":132},"SectionStudyListRecord","NsVHJSaQSjiawxIEL9cdPw","Open for Recruitment","Past Studies",{"__typename":124,"id":134,"outerColor":135,"innerColor":137,"pullUp":38},"M4a2DdyaSc-RLzkAe_eQyg",{"hex":136},"#181818",{"hex":138},"#51568E",[140,143,147,150,154,157,160,164,168,172,175,178,182,185,189,192,196],{"attributes":13,"content":141,"tag":142},"Clinical Trials | Realising the hope","title",{"attributes":144,"content":13,"tag":146},{"property":145,"content":58},"og:title","meta",{"attributes":148,"content":13,"tag":146},{"name":149,"content":58},"twitter:title",{"attributes":151,"content":13,"tag":146},{"name":152,"content":153},"description","In our pursuit of innovation and excellence, we are committed to fostering collaborative partnerships that drive the boundaries of healthcare forward.",{"attributes":155,"content":13,"tag":146},{"property":156,"content":153},"og:description",{"attributes":158,"content":13,"tag":146},{"name":159,"content":153},"twitter:description",{"attributes":161,"content":13,"tag":146},{"property":162,"content":163},"og:image","https://www.datocms-assets.com/132841/1717490760-og-image.jpg?auto=format&fit=max&w=1200",{"attributes":165,"content":13,"tag":146},{"property":166,"content":167},"og:image:width","1200",{"attributes":169,"content":13,"tag":146},{"property":170,"content":171},"og:image:height","630",{"attributes":173,"content":13,"tag":146},{"name":174,"content":163},"twitter:image",{"attributes":176,"content":13,"tag":146},{"property":177,"content":32},"og:locale",{"attributes":179,"content":13,"tag":146},{"property":180,"content":181},"og:type","article",{"attributes":183,"content":13,"tag":146},{"property":184,"content":6},"og:site_name",{"attributes":186,"content":13,"tag":146},{"property":187,"content":188},"article:modified_time","2024-06-24T08:04:45Z",{"attributes":190,"content":13,"tag":146},{"property":191,"content":37},"article:publisher",{"attributes":193,"content":13,"tag":146},{"name":194,"content":195},"twitter:card","summary",{"attributes":197,"content":13,"tag":146},{"name":198,"content":199},"twitter:site","@CellsightT",{"_allStudiesMeta":201,"allStudies":203},{"count":202},20,[204,211,217,223,228,234,239,245,251,257,263,268,273,279,285,291,296,302,308,314],{"_modelApiKey":205,"id":206,"openForRecruitment":39,"date":207,"title":208,"author":209,"authorRole":37,"html":210,"externalLink":37},"study","XhvCAvUiR6SdrJ1qXOrdzw","2024-02-02","Assessment of PET Tracers to Evaluate T Cell Change and Activation in Relation to Immunotherapy Treatment Response in Non-Small Cell Lung Cancer ","Idris Bahce M.D., Ph.D. I Amsterdam UMC","\u003Cp>This PET imaging trial will compare two promising T cell PET tracers alongside the pathological analysis of the resected tumor. Following chemo-immunotherapy, NSCLC patients will undergo two PET scans shortly before their surgery.\u003C/p>",{"_modelApiKey":205,"id":212,"openForRecruitment":39,"date":213,"title":214,"author":215,"authorRole":37,"html":216,"externalLink":37},"MT7UQ-d1QNa4bd4TWwD0eg","2023-01-02","[18F]F-AraG PET imaging of Non Small Cell Lung Cancer patients undergoing checkpoint inhibitor immunotherapy","Yuji Nakamoto M.D. Ph.D. and Tomomi W Nobashi M.D. I Kyoto University","\u003Cp>This study explores tumoral uptake of [18F]F-AraG and its association with the treatment effect of immune checkpoint inhibitors for stage 4 NSCLC patients. [18F]F-AraG PET/CT scanning will be performed twice per patient, pre and post start of immunotherapy. The uptake difference in tumor and associated lymphoid organs will be considered for the analysis, as well as the correlation with the expression of CD8, PD-1 and Treg markers in immunohistochemistry. CellSight is providing [18F]F-AraG precursor free of charge.\u003C/p>",{"_modelApiKey":205,"id":218,"openForRecruitment":39,"date":219,"title":220,"author":221,"authorRole":37,"html":222,"externalLink":37},"GrKDTpuDRdWAiSzDoUpC2A","2023-01-01","Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG ","Muhammad Furqan M.D. I Holden Comprehensive Cancer Center","\u003Cp>This pilot study uses [18F]F-AraG PET imaging to evaluate the immunological response to inhibitor therapy (CkIT) in patients with advanced NSCLC tumors. \u003C/p>",{"_modelApiKey":205,"id":224,"openForRecruitment":39,"date":219,"title":225,"author":226,"authorRole":37,"html":227,"externalLink":37},"RkHXhBYbRleeHgut_2uBjA","Test-retest Evaluation of [18F]F-AraG PET","John Sunderland Ph.D. and Muhammad Furqan M.D. I Holden Comprehensive Cancer Center","\u003Cp class=\"p1\">This pilot study aims to evaluate the test-retest variability of [\u003Cspan class=\"s1\">\u003Csup>18\u003C/sup>\u003C/span>F]F-AraG-PET imaging in patients with advanced NSCLC tumors.\u003C/p>",{"_modelApiKey":205,"id":229,"openForRecruitment":39,"date":230,"title":231,"author":232,"authorRole":37,"html":233,"externalLink":37},"KiMiNaZqS4OAu4kLAeppSA","2022-01-01","A Clinical Imaging Study of the Changes in [18F]F-AraG Uptake Following Anti-PD-1 Therapy in Non-small Cell Lung Cancer (SHARP)","Idris Bahce M.D., Ph.D. I Amsterdam UMC ","\u003Cp class=\"p1\">The aim of the SHARP trial is to investigate changes in [\u003Cspan class=\"s1\">\u003Csup>18\u003C/sup>\u003C/span>F]F-AraG uptake following Anti-PD-1 therapy in patients with non-small cell lung cancer (NSCLC).\u003C/p>",{"_modelApiKey":205,"id":235,"openForRecruitment":39,"date":230,"title":236,"author":237,"authorRole":37,"html":238,"externalLink":37},"bh0G1qEASlGIwc0T6W8LXg","A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors","Shivaani Kummar M.D. , Erik Mittra M.D. and Carina Mari Aparici M.D. I Oregon Health and Science University and  Stanford University","\u003Cp>In this study, patients with advanced solid tumors will undergo [18F]F-AraG PET/CT imaging to assess for changes in tracer uptake following treatment with CkIT.\u003C/p>",{"_modelApiKey":205,"id":240,"openForRecruitment":39,"date":241,"title":242,"author":243,"authorRole":37,"html":244,"externalLink":37},"Q9yl9bB6Rq6tpLA4XRQaiw","2021-05-01"," [18F]F-AraG/Total Body PET Imaging and Healthy Subjects and Lung Cancer Patients","Simon R Cherry Ph.D. I University of California, Davis","\u003Cp class=\"p1\">In this pilot study, healthy volunteers and patients with Non-Small Cell Lung Cancer will undergo [\u003Cspan class=\"s1\">\u003Csup>18\u003C/sup>\u003C/span>F]F-AraG dynamic imaging on the uEXPLORER total body PET/CT scanner to obtain preliminary data regarding pharmacokinetics and early biodistribution images.\u003C/p>",{"_modelApiKey":205,"id":246,"openForRecruitment":39,"date":247,"title":248,"author":249,"authorRole":37,"html":250,"externalLink":37},"fwuK_2psQ5urssnlKOkBDQ","2021-04-01","Imaging of T-cell Activation With [18F]F-AraG in Advanced Non-Small Cell Lung Cancer (NSCLC)","Millie Das M.D., Minal Vasanawala M.D., and Deepti Behl M.D. I Palo Alto Veteran’s Affairs and Sutter Medical Center","\u003Cp class=\"p1\">This is a pilot study using [\u003Cspan class=\"s1\">\u003Csup>18\u003C/sup>\u003C/span>F]F-AraG PET imaging to evaluate the immunological response to checkpoint inhibitor therapy (CkIT) in patients with advanced NSCLC tumors at multiple study sites.\u003C/p>",{"_modelApiKey":205,"id":252,"openForRecruitment":39,"date":253,"title":254,"author":255,"authorRole":37,"html":256,"externalLink":37},"FJMzqrOXTauxe1uc9P4XRA","2021-03-01","Imaging Immune Activation in COVID-19","Timothy Henrich M.D. I University of California, San Francisco","\u003Cp class=\"p1\">This is a single arm exploratory imaging study involving up to two intravenous microdoses of [\u003Cspan class=\"s1\">\u003Csup>18\u003C/sup>\u003C/span>F]F-AraG (the second tracer dose is optional) followed by whole-body PET-CT imaging in participants with convalescent COVID-19.\u003C/p>",{"_modelApiKey":205,"id":258,"openForRecruitment":39,"date":259,"title":260,"author":261,"authorRole":37,"html":262,"externalLink":37},"Dc87MYkJRFidFNaOeeAgDA","2021-01-02","18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma","David Miklos M.D., Ph.D. I Stanford University","\u003Cp class=\"p1\">This is a pilot study in adult subjects with aggressive B-cell lymphoma who will receive commercial or research CAR T cell therapy as anticancer treatment.\u003C/p>",{"_modelApiKey":205,"id":264,"openForRecruitment":39,"date":265,"title":266,"author":232,"authorRole":37,"html":267,"externalLink":37},"fVRMGwllTfqADXX7Xcoh9Q","2021-01-01"," [18F]F-AraG PET Imaging to Visualize Tumor Infiltrating T-cell Activation in Non-small Cell Lung Cancer (ATTAIN)","\u003Cp class=\"p1\">The aim of the ATTAIN trial is to investigate the pharmacokinetic characteristics of [\u003Cspan class=\"s1\">\u003Csup>18\u003C/sup>\u003C/span>F]F-AraG by performing a full kinetic modelling, assess test-retest (TRT) variability and to correlate the tumor tracer uptake with the pathological assessment.\u003C/p>",{"_modelApiKey":205,"id":269,"openForRecruitment":38,"date":265,"title":270,"author":271,"authorRole":37,"html":272,"externalLink":37},"D7dZXcjVQYmi1pibizcelQ","PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC)","Martin Pomper M.D., Ph.D. I Johns Hopkins University","\u003Cp>This is a prospective clinical trial in patients with non-small cell lung cancer (NSCLC) undergoing PD-1/PD-L1-directed therapy. This research is being done to find out if [18F]F-AraG is a helpful imaging agent for detecting changes in cancer's anti-tumor immune response levels for NSCLC patients who will receive a cancer immunotherapy regimen.\u003C/p>",{"_modelApiKey":205,"id":274,"openForRecruitment":38,"date":275,"title":276,"author":277,"authorRole":37,"html":278,"externalLink":37},"HUyv90PQRQajzB5O6zZQbQ","2020-01-01","Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab","Diwakar Davar M.D., M.Sc. I University of Pittsburgh Medical Center","\u003Cp>The main goal of this research study is to determine how nivolumab and nivolumab/Vidutolimod (CMP-001) combination affect the likelihood of destroying melanoma involving lymph node and/or in-transit/satellite areas.\u003C/p>",{"_modelApiKey":205,"id":280,"openForRecruitment":38,"date":281,"title":282,"author":283,"authorRole":37,"html":284,"externalLink":37},"PB4XAuCmRnee2jqAcmPLJA","2019-01-01","Biodistribution and Kinetics of 18F-AraG in Non-Small Cell Lung Cancer","Dustin Osborne Ph.D. I University of Tennessee","\u003Cp>This study is to assess the biodistribution and kinetics of [18F]F-AraG in non-small cell lung cancer patients undergoing immunotherapy with and without adjuvant radiation therapy.\u003C/p>",{"_modelApiKey":205,"id":286,"openForRecruitment":39,"date":287,"title":288,"author":289,"authorRole":37,"html":290,"externalLink":37},"ayOzsVIBTWaI29aI-jKdLw","2018-01-01","Imaging Immune Activation in HIV by PET-MR","Timothy J Henrich M.D. I University of California, San Francisco","\u003Cp class=\"p1\">This study involves one intravenous microdose of [\u003Cspan class=\"s1\">\u003Csup>18\u003C/sup>\u003C/span>F]F-AraG followed by whole-body positron emission tomography-magnetic resonance (PET-MR) imaging in HIV infected individuals to determine the anatomical distribution of the PET tracer.\u003C/p>",{"_modelApiKey":205,"id":292,"openForRecruitment":38,"date":287,"title":293,"author":294,"authorRole":37,"html":295,"externalLink":37},"fjDVgIoDTN6UmFWEoSoH2Q","Detection of Graft Versus Host Disease With [18F]F-AraG","Sanjiv Gambhir M.D., Ph.D. I Stanford University","\u003Cp>This study determines the utility of in vivo imaging with [18F]F-AraG to identify sites of Graft Versus Host Disease (GVHD) in patients highly suspected of having acute GVHD who require systemic therapy, and patients at high risk for developing acute GVHD.\u003C/p>",{"_modelApiKey":205,"id":297,"openForRecruitment":38,"date":298,"title":299,"author":300,"authorRole":37,"html":301,"externalLink":37},"UQ0B1aEOQ0qszIJy5zWxJQ","2017-03-01","Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1","Lawrence Fong M.D. I University of California, San Francisco","\u003Cp>This phase II trial studies how well [18F]F-AraG PET/MR imaging works in measuring clinical response to atezolizumab or patients with cancer receiving standard of care Anti-PD-1/L1.\u003C/p>",{"_modelApiKey":205,"id":303,"openForRecruitment":38,"date":304,"title":305,"author":306,"authorRole":37,"html":307,"externalLink":37},"PqygxbHgSWur6WRmH4DpIg","2017-02-01","Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)","A. Dimitrios Colevas M.D. I Stanford University","\u003Cp>This is a cross-sectional imaging and correlative biomarker study in patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN). Two whole body PET/CT images with [18F]F-AraG, blood samples, and tissue biopsies will be collected from patients.\u003C/p>",{"_modelApiKey":205,"id":309,"openForRecruitment":38,"date":310,"title":311,"author":312,"authorRole":37,"html":313,"externalLink":37},"Vx2iol6qSBOepVHEnkVf5Q","2017-01-01"," [18F]FAraG PET Imaging for Analysis of Biodistribution in Cancer Patients Expected to Undergo Immunotherapy and/or Radiation Therapy","Robert R Flavell M.D., Ph.D. I UCSF Department of Radiology and Biomedical Imaging","\u003Cp>This is a Phase 1 study is to visualize biodistribution of [18F]F-AraG (VisAcT) in cancer patients expected to undergo immunotherapy and/or radiation therapy.\u003C/p>",{"_modelApiKey":205,"id":315,"openForRecruitment":38,"date":316,"title":317,"author":318,"authorRole":37,"html":319,"externalLink":37},"ONTgYkD_Ry6FfQPs7ob6vg","2015-01-01","Study of Kinetics, Dosimetry & Safety of [18F]F-AraG, a Positron Emission Tomography Imaging Tracer in Healthy Humans","Henry Vanbrocklin Ph.D. I University of California, San Francisco","\u003Cp>The goal of this study is to visualize biodistribution of [18F]F-AraG through time in healthy human volunteers.\u003C/p>",1777360934243]